Association between 4-benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing it

Abstract

Association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. Medicinal products containing the same which are useful in the treatment of cognitive disturbances associated with cerebral ageing and with neurodegenerative diseases.

1 . A combination between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): 
       
         
           
           
               
               
           
         
       
       or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. 
     
     
         2 . The combination according to  claim 1 , wherein the 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide is in the form of an oxalate or hydrochloride. 
     
     
         3 . The combination according to  claim 1 , wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, galantamine, and pharmaceutically acceptable salts thereof. 
     
     
         4 . The combination according to  claim 3 , wherein acetylcholinesterase inhibitor is selected from donepezil hydrochloride, rivastigmine hydrogen tartrate, and galantamine hydrobromide. 
     
     
         5 . The combination according to  claim 1 , wherein 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide is administered in the form of a hydrochloride at a daily dose of 2 mg, 5 mg or 20 mg (expressed as base), and the acetylcholinesterase inhibitor is donepezil hydrochloride administered at a daily dose of 10 mg.